Multiple Myeloma
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
News
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
News
Women hematologists advance MM research, give back
At the frontiers of CAR T-cell research for myeloma, women blood cancer specialists break new ground while also coaching their younger women...
News
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
Conference Coverage
Experts debate reducing ASCT for multiple myeloma
Overall survival following multidrug regimens and transplant are on par, raising questions about the best frontline therapy for multiple myeloma...
News
Motixafortide may improve MM outcomes
A new drug approval for motixafortide is currently under review by the Food and Drug Administration.
News
From Beirut to frontline hematology research
A young Lebanese-American physician scientist keeps ‘smoldering’ myeloma in his sights and a sick relative in mind.
News
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.
News
Erythema extent predicts death in cutaneous GVHD
Study: Extent of skin erythema correlates with deaths from graft-versus-host disease in blood cancer patients after stem cell transplants.
News
Blenrep for multiple myeloma withdrawn from U.S. market
As requested by the U.S. Food and Drug Administration, the multiple myeloma drug blenrep is being taken off the market after disappointing results...
